2025-09-06 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co. (LLY), broken down as requested, with a focus on clarity and actionable insights.

## Eli Lilly and Co. (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 217.63%
*   **Cumulative Return (VOO):** 101.31%
*   **Absolute Spread:** 121.9 (LLY outperformed VOO by this percentage)
*   **Spread Range:** Max: 311.6, Min: -27.3
*   **Relative Spread:** 44.0 (The current spread is in the 44th percentile of its historical range.)

**Analysis:** LLY has significantly outperformed the S&P 500. The relative spread indicates that while the outperformance is substantial, it's not at its historical peak, suggesting potential for further upside or some consolidation.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | 10.0%   | 56.3% | -19.0%  | 0.0   | 75.7   |
| 2016-2018  | 39.0%   | 58.6% | 21.0%   | -0.1  | 103.7  |
| 2017-2019  | 50.0%   | 58.6% | 20.0%   | 0.3   | 117.8  |
| 2018-2020  | 52.0%   | 58.6% | 33.0%   | 0.1   | 151.4  |
| 2019-2021  | 106.0%  | 60.6% | 57.0%   | 0.2   | 247.6  |
| 2020-2022  | 98.0%   | 64.8% | 96.0%   | 0.2   | 328.0  |
| 2021-2023  | 133.0%  | 64.8% | 115.0%  | 0.3   | 522.6  |
| 2022-2024  | 150.0%  | 72.2% | 124.0%  | 0.2   | 692.1  |
| 2023-2025  | 71.0%   | 76.8% | 17.0%   | 0.2   | 651.9  |

**Analysis:**

*   **CAGR:** High growth rates in recent periods, especially from 2019-2024. The most recent period (2023-2025) shows a decline in CAGR, but still a positive return.
*   **MDD:** Maximum Drawdown indicates the potential for significant price declines.  The MDD has been increasing, suggesting higher volatility.
*   **Alpha:** Consistently positive Alpha indicates that LLY has generated returns above what would be expected based on the market's performance.
*   **Beta:** Beta values close to zero, suggest LLY's price is not strongly correlated with the market.
*   **Cap(B):** Market capitalization has grown substantially, reflecting the company's growth and investor confidence.

### 2. Recent Price Action

*   **Current Price:** $727.21
*   **Last Market Data:** Price: $727.21, Previous Close: $742.91, Change: -2.11%
*   **5-day Moving Average:** $735.11
*   **20-day Moving Average:** $702.38
*   **60-day Moving Average:** $753.13

**Analysis:** The price is below the 5-day and 60-day moving averages but above the 20-day moving average.  The recent price drop of -2.11% and the positioning relative to the moving averages suggest a potential short-term pullback or consolidation phase.

### 3. Market Risk Indicator & Key Metrics

*   **Market Risk Indicator (MRI):** 0.3322 (Low Risk)
*   **RSI:** 62.42 (Approaching overbought territory, but not there yet)
*   **PPO:** 0.8655 (Positive, indicating bullish momentum)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **20-Day Relative Spread Change:** 5.1 (+): Short-term increase
*   **Expected Return (%):** 206.4 (Long-term, expected outperformance vs. S&P 500)

**Analysis:**

*   **MRI:** Low risk environment according to this indicator.
*   **RSI:** Suggests increasing buying pressure, but not yet overbought.  A continued rise could signal a potential overbought condition.
*   **PPO:** Confirms the upward trend.
*   **Hybrid Signal:** Suggests buying with caution. The "Caution" flag is likely triggered by the recent price volatility.
*   **20-Day Relative Spread Change:** Supports the recent positive momentum.
*   **Expected Return:** Highly optimistic long-term outlook.

The recent price change of -2.11% indicates a short-term negative movement, potentially due to profit-taking or market fluctuations. This volatility is reflected in the Hybrid Signal's caution flag.

### 4. Recent News & Significant Events

*   **Health Care Sector Update:** Positive news for the healthcare sector provides a tailwind for LLY.
*   **WHO Adds Weight Loss Drugs:**  This is a significant development for LLY, given its focus on weight loss drugs.
*   **Jefferies Sees Huge Potential:** This positive analyst coverage likely contributes to investor confidence.
*   **Is Eli Lilly Stock a Buy?:** The Motley Fool article suggests continued investor interest in the stock's potential.

**Analysis:** The news flow is overwhelmingly positive, particularly regarding the potential of LLY's weight loss drugs. This is a major catalyst for future growth.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.68 (~Buy)
*   **Target Price:** $891.62 (Average), $1190.00 (High), $650.00 (Low)

**Analysis:**  Strong analyst support with a consensus "Buy" rating. The average target price suggests significant upside potential from the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-08-07 | 6.3  | $15.56 B     |
| 2025-05-01 | 3.07 | $12.73 B     |
| 2024-10-30 | 1.08 | $11.44 B     |
| 2024-08-08 | 3.29 | $11.30 B     |
| 2025-08-07 | 3.29 | $11.30 B     |

**Analysis:** The most recent earnings (2025-08-07) show a significant jump in both EPS and Revenue. This likely contributed to the stock's recent positive momentum. However, the duplicated row may be data error.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $15.56B    | 84.27%        |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |
| 2024-06-30 | $11.30B    | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE      |
|------------|------------|----------|
| 2025-06-30 | $18.27B    | 30.98%   |
| 2025-03-31 | $15.76B    | 17.50%   |
| 2024-12-31 | $14.19B    | 31.07%   |
| 2024-09-30 | $14.24B    | 6.81%    |
| 2024-06-30 | $13.56B    | 21.88%   |

**Analysis:**

*   **Revenue:**  Consistent growth in revenue over the past few quarters.
*   **Profit Margin:**  Extremely high and increasing profit margins indicate strong pricing power and efficient operations.
*   **Equity:** Growing equity base suggests strong financial health.
*   **ROE:** High and fluctuating ROE suggests good profitability relative to equity. The 6.81% in 2024-09-30 could be an outlier or represent a period of higher investment.

### 7. Overall Assessment

Eli Lilly (LLY) presents a compelling picture:

*   **Strong Outperformance:**  Substantially outperforming the S&P 500.
*   **Positive Momentum:** Recent news, analyst opinions, and earnings data are all positive.
*   **Solid Financials:** High revenue growth, exceptional profit margins, and a healthy balance sheet.
*   **Key Catalyst:**  The potential of its weight loss drugs is a major growth driver.
*   **Potential Risks:** The stock isn't cheap, but it is below the analyst target price, the MDD indicates the potential for significant price declines and the RSI is approaching overbought territory, suggesting a possible short-term pullback.

**Recommendation:**  LLY appears to be a good long-term investment, but investors should be aware of the risks and volatility, the MDD and recent -2.11% price change highlight this risk. A potential strategy would be to accumulate shares gradually, especially during any price dips. The "Hybrid Signal" recommendation of "Buy with Caution" seems appropriate.
